Sun Pharma Laboratories has informed that with reference to the earlier announcement regarding Outcome of the Adjourned Board Meeting held on May 26, 2017 where the Company have mentioned that Uday Baldota ‘would be shifting to United States of America, to look after the business of Taro Pharmaceutical Industries, a subsidiary of the Company’ request to read it as ‘would be shifting to United States of America, to look after the business of Taro Pharmaceutical Industries Limited, a subsidiary of the Parent Company, Sun Pharmaceutical Industries Limited’.
The above information is a part of company’s filings submitted to BSE.
